T cell survival/proliferation reconstitution by trifluoperazine in human immunodeficiency virus-1 infection

Virology

Volumn 315, Issue 1, 2003, Pages 245-258

  Achour, Ammar ^a,c   Lu, Wei ^a   Arlie, Marine ^b   Cao, Li ^a   Andrieu, Jean Marie ^a,b  

^a Centre Universitaire des Saints Peres   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Amphiphilic; Cationic; HIV 1; Immunity; Pathogenesis; Therapy; Trifluoperazine

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; TRIFLUOPERAZINE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MOLECULE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0242268127     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00535-X     Document Type: Article

References (43)

1. Achour A., Landureau J.C., Salerno-Goncalves R., Mazière J.C., Zagury D. Restoration of the immune response by a cationic amphiphilic drug (AY 9944) in vitro a new approach towards chemotherapy against HIV-1 . Antimicrobial. Agents Chemother. 42:1998;2482-2491.
2. Achour A. Increased β. chemokines production in peripheral blood mononuclear cells derived from HIV-1-infected individuals by a cationic amphiphilic drug (AY 9944) in vitro. AIDS. 14:2000;1454-1455.
3. Achour A. The cationic amphiphilic molecules as potential immunostimulants for HIV-1 infection. Int. J. Antimicrob. Agents. 18:2001;275-276.
4. Achour A. Potentiation of immune system by cationic amphiphilic drugs. Trends Pharmacol. Sci. 23:2002;161.
5. Ameissen J.C., Capron A. Cell dysfunction and depletion in AIDS; the programmed cell death hypothesis. Immunol. Today. 12:1991;102-105.
6. Autran B., Garcelin G., Li T.S., Blanc C., Mathez D., Tubiana R., Katlama C., Debre P., Leibovitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116.
7. Bohler T., Walcher J., Holzl-Weinig G., Geiss M., Buchholz B., Linde R., Debatin K.M. Early effects of antiretroviral combibaison therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. AIDS. 13:1999;779-789.
8. Bohr W., Ratter G., Hohenberg H., Manweiler K. Inhibition of measles virus budding by phenothiazines. Virology. 130:1983;44-45.
9. Breugnot C., Mazière C., Salmon S., Auclair M., Santus R., Morlière P., Lenares A., Mazière J.C. Phenothiazines inhibit copper and endothelial cell-induced peroxidation of low density lipoprotein. Biochem. Pharmacol. 9:1990;419-423.
10. Broussard S.R., Staprans R., White R., Whitehead E.M., Feinberg M.B., Alain J.S. Simian immunodeficiency virus replicates to high levels in naturally infected African green mobkeywithout inducing immunologic or neurologic disease. J. Virol. 75:2001;2262-2275.
11. Butera S.T. Therapeutic targeting of human immunodeficiency virus type-1 latency current clinical realities and future scientific possibilities . Antivir. Res. 48:2000;143-176.
12. Chun T.W., Engel D., Mizell S.B., Hallahan C.W., Fischette M., Park S., Davey R.T., Dybul M., Kovacs J.A., Metcaff J.A., Mican J.M., Berrey M.M., Corey L., Lane H.C., Fauci A.S. Effect of Interleukin-2 on the pool of latently infected resting T cells in HIV-1 infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5:1999;651-655.
13. Clerici M., Lucey D.R., Berzofsky J.A., Pinto L.A., Wynn T.A., Blatt S.P., Dolan M.J., Hendrix G.W., Wolf S.F., Shearer G.M. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science. 262:1993;1721-1724.
14. Copeland K.F., Heeney G.L. T helper cell activation and human retroviral pathogenesis. Micro. Rev. 60:1996;722-742.
15. Dam-Nielsen S., Kjaer Ersboll A., Mathiesen L., Nielsen J.O., Hensen J.E. Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients. J. Infect. Dis. 178:1998;1299-1305.
16. Deeks R.G., Hoh R., Grant M., Wrin T., Barbour J.D., Narvaez A., Cesar D., Abe K., Hanley M.B., Hellmann N.S., Petropoulos C.J., McCune J.M., Hellerstein M.K. CD4 T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long treatment with protease inhibitor-based therapy. J. Infect. Dis. 85:2000;315-323.
17. Dyrhol-Riise A.M., Voltersvick P., Olofsson J., Asjo B. Activation of CD8 T cells normalises and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV1 infection. AIDS. 13:1999;2365-2376.
18. Fauci A.S. Multifactorial nature of human immunodeficiency virus implications for therapy . Science. 262:1993;1011-1018.
19. Finkel T.H., Tudor-Williams G., Banda N.K., Cotton M.F., Curiel T., Monks C., Baba T.W., Ruprecht R.M., Kupfer A. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat. Med. 1:1995;129-134.
20. Hait W.N., Lee G.I. Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists. Biochem. Pharmacol. 34:1985;3973-3978.
21. Hazenberg M.T.L., Cohen Stuart J.W.T., Otto S.A., Borleffs J.C.C., Boucher C.A.B., de Boer R.J., Miedena F., Hamann D. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation a longigutinal analysis in patients before and during highly active antiretroviral therapy (HAART) . Blood. 95:2000;249-255.
22. Hengel R.L., Jones B.M., Kenned M.S., Hubbard M.R., McDouglas J.S. Lymphocyte kinetics and precursor frequency-dependent recovery of CD4 (+) CD45RA (+) CD62L (+) naïve T cells following triple-drug therapy for HIV type 1 infection. AIDS Res. Hum. Retroviruses. 15:1999;435-443.
23. Ho D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markwitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 3373:1995;123-126.
24. Jeding I., Evans P.J., Akamu D., Dexter D., Spencer J.D., Aruoma O.I., Jenner P., Halliwell B. Characterisation of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem. Pharmacol. 49:1995;359-365.
25. Kaur A., Grant R.M., Mans R.E., Mc Lure H., Feinberg M., Johnson R.P. Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J. Virol. 72:1998;9597-9611.
26. Krizanova O., Ciampor F., Weber P. Influence of chlorpromazine on the replication of influenza virus in chick embryo cells. Acta. Virol. 26:1982;209-216.
27. Ledermann M.M., Connick E., Landay A., Kuritzkes D.R., Spritzler J., St. Clair M., Kotzin B.L., Fox L., Chiozzi M.H., Leonard J.M., Rousseau F., Wade M., Roe J.D., Martinez A., Kessler H. Immunologic response associated with 12 weeks of combinaison antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir results of AIDS Clinical Trials Group Protocol 315 . J. Infect. Dis. 178:1998;70-79.
28. Levin R.M., Weiss B. Binding of trifluoperazine to the calcium-dependent activator of cyclic nucleotide phosphodiestrase. Mol. Pharmacol. 13:1977;690-697.
29. Lu W., Achour A., Arlie M., Cao L., Andrieu J.M. Enhanced dentritic cell-driven proliferation and anti-HIV activity of CD8+ T cells by a new phenothiazine derivative, aminoperazine. J. Immunol. 167:2001;2929-2935.
30. Lu W., Andrieu J.M. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro a viral-suppression-independent mechanism . Blood. 96:2000;50-258.
31. Lu W., Cao L., Ty L., Arlie M., Andrieu J.M. Equivalent amplification of intrinsically variable nucleic acid sequence by multiple-primer-induced overlapping amplification assay for universal detection and quantitation. Nat. Med. 5:1999;1081.
32. Mazière C., Mazière J.C., Mora L., Auclair M., Polonovski J. Trifluoperazine increases fatty acid turnover in phospholipids in cultured human fibroblasts. Lipids. 23:1988;419-423.
33. Micoli K.J., Pan G., Wu Y., Williams J.P., Cook W.J., McDonald M. Requirement of calmodulin binding by HIV-1 gp160 for enhanced FAS-mediated apoptosis. J. Biol. Chem. 275:2000;1233-1240.
34. Nel A.E., Dirienzo W., Stefanini G.F., Wooten M.W., Canonica G.W., Lattanze G.R., Stevenson H.C., Miller P., Fudenberg H.H., Galbraith R.M. Inhibition of T3 mediated T-cell proliferation by Ca2+-chanel blocckers and inhibitors of Ca2+/phospholipid-dependent kinase. Scand. J. Immunol. 24:1986;3973-3978.
35. Ochiai H., Kurukowa M., Miwayama S. Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells. Antiviral Res. 15:1991;149-160.
36. Pakker N.G., Notermans D.W., DeBoer R.J., Roos M.T., de Wolf F., Hill A., Leonard J.M., Danner S.A., Miedena F., Schellekens P.T. Biphasics kinetics of peripheral blood T lymphocytes after triple combinasion therapy in HIV-1 infection a composite of redistribution and proliferation . Nat. Med. 4:1998;208-214.
37. Pan G., Zhou T., Radding W., Saag M.S., Mountz J.D., McDonald M. Calmodulin antagonists inhibit apoptosis of CD4+ T cells from patients with AIDS. Immunopharmacology. 40:1998;91-103.
38. Pantaleo G. How immune-based interventions can change HIV therapy. Nat. Med. 5:1997;483-486.
39. Slater T.F. The inhibitory effects in vivo of phenothiazines and other drugs on lipid peroxidation systems in rat liver microsomes and their relationships to liver necrosis produced by carbon tetrachloride. Biochem. J. 106:1968;155-159.
40. Sousa A.E., Carneiro J., Meier-Schellersheim M., Grossman Z., Victorino R.M.M. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 169:2002;3400-3406.
41. Srinivas R.V., Bernstein H., Oliver C., Compans R.W. Calmodulin antagonists inhibit human immunodeficiency virus-induced cell fusion but not virus replication. AIDS. Res. Hum. Retroviruses. 10:1994;1489-1496.
42. Wei X., Ghosh S.J., Taylor M.E., Johnson V.A., Emini E.A., Deutsh P., Lifson S., Bonheffer J.D., Nowak M.A., Hahn B.H., Saag M.S., Shaw G.M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
43. Zinkernagel R.M., Hengartner H. T-cell-mediated immunopathology versus direct cytolysis by virus implications for HIV and AIDS . Immunol. Today. 6:1994;262-268.